2 registrations that name bifidobacterium bifidum as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT06719596
Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Complications in PD
Phase 1 and 2
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
About 68 people
Started May 10, 2024
In plain words A Phase 1 and 2 study of bifidobacterium bifidum in people 18 and older, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It plans to enroll about 68 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Infectious Complications.
Adult patients greater than 18 years of age;
Indication for elective pancreaticoduodenal surgery;
Patients who understand the nature of the trial and are willing and able to provide written consent
The exclusion criteria are on the listing.
What it tests, as registered
Bifidobacterium Bifidum Oral Capsule
Registered summary
Probiotics combined with enteral nutrition reduces postoperative infectious complications in PD
Where, as registered
No US site; China (1).
RecruitingNCT07754968
Use of Bifidobacterium Bifidum in Formula-Fed Infants With Colic, With or Without Atopic Dermatitis
No phase
University of Roma La Sapienza
About 64 people
Started Jul 1, 2026
In plain words A study of bifidobacterium bifidum in people 1 week to 5 months, run by University of Roma La Sapienza. It plans to enroll about 64 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 1 week to 5 months; healthy volunteers accepted. Conditions: Infant Colic; Atopic Dermatitis.
Non-breastfed infants aged ≤ 5 months diagnosed with infant colic according to Rome IV criteria, with or without atopic dermatitis.
Written informed consent from parents or legal guardians.
The exclusion criteria are on the listing.
What it tests, as registered
Bifidobacterium bifidum BFP19® and BFP29® (Bifipral®); Placebo
Registered summary
The goal of this clinical trial is to evaluate whether daily probiotic supplementation with Bifidobacterium bifidum (Bifipral® drops) can reduce crying time in formula-fed infants aged 5 months or younger diagnosed with infant colic (according to Rome IV criteria), with or without concomitant atopic dermatitis. The main questions it aims to answer are: * Does daily administration of B. bifidum for 8 weeks achieve at least a 50% reduction in average daily crying duration compared to placebo? * Does B. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
ClinicalTrials.gov lists 22 open registrations for this search, including ones where bifidobacterium bifidum is not a study arm or that are past the 2 we keep. Search them on ClinicalTrials.gov (opens in new tab).